Loading...
•
Sep 30, 2020
Matinas BioPharma Q3 2020 Earnings Report
Matinas BioPharma reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.
Key Takeaways
Matinas BioPharma reported a net loss attributable to common shareholders of $5.7 million, or $0.03 per share, for the third quarter of 2020. The company's cash, cash equivalents, and marketable securities were approximately $62.8 million as of September 30, 2020.
EnACT study of MAT2203 received unanimous DSMB recommendation to proceed into second patient cohort.
ENHANCE-IT study of MAT9001 fully enrolled with topline data anticipated Q1 2021.
Phase 3 program on track to initiate H1 2021.
Cash on hand is sufficient to fund operations into the first half of 2023.